Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-88.82	-92.93	2.3
Depreciation & Amortization	1.43	1.11	1.13
Loss (Gain) From Sale of Assets	3.41	3.34	0
Asset Writedown & Restructuring Costs	83.1	83.1	-
Loss (Gain) on Equity Investments	0.17	1.31	0.25
Stock-Based Compensation	7.55	7.28	13.37
Provision & Write-off of Bad Debts	0.1	-0.06	0.02
Other Operating Activities	3.86	6.02	1.4
Change in Accounts Receivable	-5.07	1.4	-7.92
Change in Inventory	-1.84	1.75	-0.88
Change in Accounts Payable	0.24	0.19	-0.11
Change in Income Taxes	-2.42	3	-1.34
Change in Other Net Operating Assets	0.77	10.38	2.46
Operating Cash Flow	2.48	25.89	10.68
Operating Cash Flow Growth	-88.76%	142.50%	-
Capital Expenditures	-4.7	-8.52	-4.99
Sale of Property, Plant & Equipment	0.43	0.66	-
Cash Acquisitions	5.46	5.46	-
Divestitures	-0.57	-0.57	-
Sale (Purchase) of Intangibles	-0	-0.07	-0.01
Investment in Securities	-17.16	-16.74	-8.82
Investing Cash Flow	-16.54	-19.76	-13.81
Financing Cash Flow	3.64	2.5	-
Foreign Exchange Rate Adjustments	0.21	-0.3	-1.89
Net Cash Flow	-10.21	8.33	-5.03
Free Cash Flow	-2.23	17.38	5.69
Free Cash Flow Growth	-	205.25%	-
Free Cash Flow Margin	-2.12%	15.32%	5.56%
Free Cash Flow Per Share	-0.03	0.26	0.08
Cash Income Tax Paid	8.72	6.35	6.31
Levered Free Cash Flow	-	20.67	-
Unlevered Free Cash Flow	-	20.67	-
Change in Net Working Capital	-	-8.85	-

Source: S&P Capital IQ. Standard template. Financial Sources.